摘要
目的评价厄贝沙坦氢氯噻嗪片初始治疗2级高血压的疗效及安全性。方法采用自身对照,开放单一治疗试验设计方法,对80例新发2级高血压病人口服厄贝沙坦氢氯噻嗪片1片,4周时血压不达标则剂量加倍,观察8周,记录治疗前后诊所血压及24 h动态血压的变化,观察不良反应,以评价疗效与安全性。结果厄贝沙坦氢氯噻嗪片治疗1周后血压即有明显下降,8周后,收缩压/舒张压分别降低33.25/23.04 mm Hg(P<0.01)。治疗4周、8周、24 h、白昼与夜间血压平均值均有明显下降,血压负荷及晨峰血压明显降低。以血压<140/90 mm Hg为降压达标,治疗2、4和8周末的血压达标率分别为60%、65%、90%。未见明显不良反应。结论厄贝沙坦氢氯噻嗪片初始治疗2级高血压起效快,降压平稳,不良反应少,有利于提高病人依从性,提高血压控制达标率。
Objective To study the efficacy and safety of irbesartan/HCTZ as initial therapy for moderate hypertension.Methods In this open,single therapy trial,the 80 cases of patients with moderate hypertention who were untreated before received fixed-dose irbesartan 150 mg/HCTZ 12.5 mg combination therapy for 8 weeks,one tablet of irbesartan（150 mg）/HCTZ（12.5 mg） once a day during the first 4 weeks.If blood pressure was greater than140/90 mm Hg at the end of the fourth week,two tablets of irbesartan（150 mg）/HCTZ（12.5 mg） would be given once a day.To evaluate the efficacy and safety of the therapy,the seated blood pressure and 24 h ABPM（ambulatory blood pressure monitoring）were recorded before and after therapy,and to observe the effectiveness and bad reaction.Results After 1 week of treatment by irbesartan/HCTZ,blood pressure decreased significantly,and after 8 weeks,systolic blood pressure decreased by 33.25 mm Hg and diastolic blood pressure decreased by 23.04 mm Hg.Twenty-four hours daytime and night-time mean blood pressure（BP）,BP load,and morning blood pressure surge were reduced obviously after 4 weeks and 8 weeks treatment.The control rate was 60% at the end of the second week and 65% at the end of the 4th week and 90% at the end of the 8th week.No obvious adverse reactions were noted.Conclusion When irbesartan/HCTZ fixed-dose combination are used as initial therapy for moderate hypertension,an early BP goal can be achieved,the proportion of patients reaching blood pressure target is high with good compliance and rare adverse reactions.
出处
《哈尔滨医药》
2011年第1期2-3,共2页
Harbin Medical Journal
